Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 125 Show results per page	View Search Criteria \| Help With Results

Last Modified: 4/1/2000 First Published: 6/1/1998


1.		Phase IV Study of Amifostine for Chemotherapy Induced Peripheral Neuropathy in Patients with Cancer (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care				Completed				18 and over				Pharmaceutical / Industry				RNSMC-AM9702 ALZA-RNSMC-AM9702, NCI-V98-1390, NCT00003252

Last Modified: 11/1/2001 First Published: 11/1/2001


2.		Phase II/III Randomized Study of Amifostine Followed By Protracted Fractionated Radiotherapy in Patients With Inoperable, Unresectable, or Postoperatively Recurrent Rectal Adenocarcinoma (Summary Last Modified 11/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Completed				18 to physiologic 74				NCI				UPCC-00-A-0465 NCI-T87-0232

Last Modified: 8/1/1992


3.		Phase I Pilot/Phase III Randomized Study of CDDP and Combined External-Beam/Intracavitary Radiotherapy with vs without WR-2721 in Patients with Stages IIA-IVA and Selected Stage IB Carcinoma of the Uterine Cervix

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase I				Supportive care, Treatment				Closed				no age specified								AECM-8908198 NCI-V92-0084

Last Modified: 4/1/1998


4.		Phase III Randomized Study of Radiotherapy with vs without Amifostine for Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 04/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over				Pharmaceutical / Industry				USB-WR-38 NCI-V96-1083

Last Modified: 5/23/2007 First Published: 12/1/1997


5.		Phase III Randomized Study of Amifostine in Reducing Cisplatin Induced Ototoxicity in Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Completed				18 and over				Pharmaceutical / Industry				UCMC-971163 ALZA-UCMC-971163, NCI-V97-1330

Last Modified: 6/3/2008 First Published: 7/1/1998


6.		Phase III Randomized Study of Amifostine Mucosal Protection in Patients With Favorable Performance Inoperable Stage II, IIIA, or IIIB Non-Small Cell Lung Cancer Receiving Sequential Induction and Concurrent Hyperfractioned Radiotherapy With Paclitaxel and Carboplatin

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over				NCI				RTOG-9801 NCT00003313, RTOG-98-01

Last Modified: 8/1/1998 First Published: 8/1/1998


7.		Phase III Randomized Study of Pentoxifylline, Ciprofloxacin, and Dexamethasone Versus Amifostine in Patients with Myelodysplastic Syndromes (Summary Last Modified 08/1998)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				21 and over				Pharmaceutical / Industry				BOSTON-VAMC-523 ALZA-97-047-ii, NCI-V98-1422

Last Modified: 6/1/2007 First Published: 12/1/1999


8.		Phase III Randomized Study of Amifostine Chemoprotection in Patients With Ovarian Epithelial Cancer Receiving Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				NCI				NU-97CC4 NCI-G99-1633, NCT00004166

Last Modified: 11/27/2006


9.		Phase III Randomized Comparison of CACP vs CACP plus WR-2721 in Patients with Disseminated Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Completed				no age specified				NCI				EST-1686 EST-1686

Last Modified: 6/1/1997


10.		Phase III Study of High-Dose CTX plus GM-CSF with vs without WR-2721 Chemoprotection in Patients with Advanced Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Completed				18 and over				NCI				CLB-9160 CALGB-9160

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute